Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | OXGR1 | Q96P68 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19791434 | 0.94 | ACP1 (0.39) | HCAR2ACP1BACE1CYP11B1CYP11B2 | |
| SCHEMBL19791437 | 0.89 | TAAR1 (0.39) | HCAR2TAAR1ACP1BACE1CYP11B1 | |
| SCHEMBL13834517 | 0.87 | SLC6A3 (0.38) | HCAR2ACP1 | |
| SCHEMBL13834312 | 0.86 | RPS6KA3 (0.43) | HCAR2BACE1CYP11B1CYP11B2SYK | |
| SCHEMBL12440326 | 0.85 | ABCG2 (0.40) | ACP1CYP11B1CYP11B2ABCG2IDO1 | |
| SCHEMBL2321937 | 0.85 | MAPK1 (0.40) | ACP1CYP11B1CYP11B2ABCG2IDO1 | |
| SCHEMBL13835140 | 0.85 | HCAR2 (0.36) | HCAR2ACP1CYP11B1CYP11B2SYK | |
| SCHEMBL19791400 | 0.84 | ABCG2 (0.36) | CYP11B1CYP11B2SUCNR1SYKABCG2 | |
| SCHEMBL12440325 | 0.83 | PDGFRB (0.40) | ACP1CYP11B1CYP11B2SUCNR1ABCG2 | |
| SCHEMBL12440759 | 0.82 | CA9 (0.39) | MAOBABCG2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531500-B1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-01-24 | — | — | EP | disclosed |
| EP-2531500-B1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-01-24 | — | — | EP | disclosed |
| US-8912216-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912216-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912216-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8614226-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | ATP5F1A, ATP5ME, ATP5F1D | HCAR2 2625/4885TAAR1 3530/4885ACP1 4054/4885 |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | ATP5F1A, ATP5ME, ATP5F1D | HCAR2 2625/4885TAAR1 3530/4885ACP1 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.